Citius stock rises as I/ONTAK gets FDA review for rare blood cancer

Iryna Drozd

• The U.S. Food and Drug Administration (FDA) accepted for review Citius Pharmaceuticals' (NASDAQ:CTXR) application seeking approval of denileukin diftitox (I/ONTAK or E7777) to treat patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare type of blood cancer.
• The FDA is expected to make a decision on the biologics license application (BLA) by Sept. 28, 2023.
• The BLA was backed by data from a phase 3 trial.
• I/ONTAK is a purified and more bioactive formulation of previously FDA-approved ONTAK, the company noted.
• CTXR +4.27% to $1.22 premarket Dec. 1

Comments

[john boy]

whoopie something is happening